The scale-up of CAP-1002 production and the progress in the HOPE-3 Phase 3 clinical trial are significant developments for Capricor Therapeutics. These steps indicate positive momentum in their product development and clinical trials, which are critical for the company's future growth and success. The news is likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.